<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>APOQUEL- oclacitinib maleate tablet, coated </strong><br>Zoetis Inc.<br></p></div>
<h1>apoquel<span class="Sub">®</span><br> (oclacitinib tablet)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">For oral use in dogs only</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">Caution</span>: Federal (USA) Law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<p class="First"><span class="Bold">Description</span>: APOQUEL (oclacitinib maleate) is a synthetic Janus Kinase (JAK) inhibitor. The chemical composition of APOQUEL is N-methyl[trans-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclohexyl]methanesulfonamide (2Z)-2-butenedioate.</p>
<p>The chemical structure of oclacitinib maleate is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=275a2c51-9679-4f42-b8cc-21b04369a056&amp;name=apoquel-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<p class="First"><span class="Bold">Indications</span>: Control of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> associated with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span> and control of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> in dogs at least 12 months of age.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-5"></a><p></p>
<p class="First"><span class="Bold">Dosage and Administration</span>: The dose of APOQUEL (oclacitinib maleate) tablets is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy. APOQUEL may be administered with or without food.</p>
<table width="60%">
<caption><span>Dosing Chart</span></caption>
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="13%">
<col align="center" valign="middle" width="2%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" colspan="2">Weight Range<br>(in lb)</th>
<th class="Rrule" align="center" colspan="2">Weight Range<br>(in Kg)</th>
<th class="Rrule" align="center"> </th>
<th class="Rrule" align="center" colspan="3">Number of Tablets to be Administered</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Low</th>
<th class="Rrule" align="center">High</th>
<th class="Rrule" align="center">Low</th>
<th class="Rrule" align="center">High</th>
<th class="Rrule" align="center"> </th>
<th class="Rrule" align="center">3.6 mg Tablets</th>
<th class="Rrule" align="center">5.4 mg Tablets</th>
<th class="Rrule" align="center">16 mg Tablets</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">6.6</td>
<td class="Rrule" align="center">9.9</td>
<td class="Rrule" align="center">3.0</td>
<td class="Rrule" align="center">4.4</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"><span class="Bold">0.5</span></td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">10.0</td>
<td class="Rrule" align="center">14.9</td>
<td class="Rrule" align="center">4.5</td>
<td class="Rrule" align="center">5.9</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center"><span class="Bold">0.5</span></td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">15.0</td>
<td class="Rrule" align="center">19.9</td>
<td class="Rrule" align="center">6.0</td>
<td class="Rrule" align="center">8.9</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"><span class="Bold">1</span></td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">20.0</td>
<td class="Rrule" align="center">29.9</td>
<td class="Rrule" align="center">9.0</td>
<td class="Rrule" align="center">13.4</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center"><span class="Bold">1</span></td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">30.0</td>
<td class="Rrule" align="center">44.9</td>
<td class="Rrule" align="center">13.5</td>
<td class="Rrule" align="center">19.9</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center"><span class="Bold">0.5</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">45.0</td>
<td class="Rrule" align="center">59.9</td>
<td class="Rrule" align="center">20.0</td>
<td class="Rrule" align="center">26.9</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center"><span class="Bold">2</span></td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">60.0</td>
<td class="Rrule" align="center">89.9</td>
<td class="Rrule" align="center">27.0</td>
<td class="Rrule" align="center">39.9</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center"><span class="Bold">1</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">90.0</td>
<td class="Rrule" align="center">129.9</td>
<td class="Rrule" align="center">40.0</td>
<td class="Rrule" align="center">54.9</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center"><span class="Bold">1.5</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">130.0</td>
<td class="Rrule" align="center">175.9</td>
<td class="Rrule" align="center">55.0</td>
<td class="Rrule" align="center">80.0</td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center"><span class="Bold">2</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<p class="First"><span class="Bold">Warnings:</span></p>
<p>APOQUEL is not for use in dogs less than 12 months of age (see <span class="Bold"><a href="#AS">Animal Safety</a></span>).</p>
<p>APOQUEL is not for use in dogs with serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>APOQUEL may increase susceptibility to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including demodicosis, and exacerbate neoplastic conditions (see <span class="Bold"><a href="#AR">Adverse Reactions</a></span> and <span class="Bold"><a href="#AS">Animal Safety</a></span>).</p>
</div>
<div class="Section" data-sectionCode="50741-8">
<a name="section-7"></a><p></p>
<p class="First"><span class="Bold">Human Warnings</span>:</p>
<p>This product is not for human use. Keep this and all drugs out of reach of children. For use in dogs only. Wash hands immediately after handling the tablets. In case of accidental eye contact, flush immediately with water or saline for at least 15 minutes and then seek medical attention. In case of accidental ingestion, seek medical attention immediately.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<p class="First"><span class="Bold">Precautions</span>:</p>
<p>APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches.</p>
<p>The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents.</p>
<p>Dogs receiving APOQUEL should be monitored for the development of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including demodicosis, and neoplasia.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-9"></a><p></p>
<p class="First"><span class="Bold">Adverse Reactions</span>:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Underline">Control of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></span></p>
<p>In a masked field study to assess the effectiveness and safety of oclacitinib for the control of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> in dogs, 152 dogs treated with APOQUEL and 147 dogs treated with placebo (vehicle control) were evaluated for safety. The majority of dogs in the placebo group withdrew from the 112-day study by Day 16. Adverse reactions reported (and percent of dogs affected) during Days 0-16 included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4.6% APOQUEL, 3.4% placebo), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3.9% APOQUEL, 4.1% placebo), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (2.6% APOQUEL, 0% placebo), new cutaneous or subcutaneous lump (2.6% APOQUEL, 2.7% placebo), and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (2.0% APOQUEL, 1.4% placebo). In most cases, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> spontaneously resolved with continued dosing. Dogs on APOQUEL had decreased leukocytes (neutrophil, eosinophil, and monocyte counts) and serum globulin, and increased <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and lipase compared to the placebo group but group means remained within the normal range. Mean lymphocyte counts were transiently increased at Day 14 in the APOQUEL group.</p>
<p>Dogs that withdrew from the masked field study could enter an unmasked study where all dogs received APOQUEL. Between the masked and unmasked study, 283 dogs received at least one dose of APOQUEL. Of these 283 dogs, two dogs were withdrawn from study due to suspected treatment-related adverse reactions: one dog that had an intense flare-up of <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> and severe secondary <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span> after 19 days of APOQUEL administration, and one dog that developed generalized demodicosis after 28 days of APOQUEL administration. Two other dogs on APOQUEL were withdrawn from study due to suspected or confirmed malignant neoplasia and subsequently euthanized, including one dog that developed signs associated with a heart base <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> after 21 days of APOQUEL administration, and one dog that developed a Grade III mast cell tumor after 60 days of APOQUEL administration.</p>
<p>One of the 147 dogs in the placebo group developed a Grade I mast cell tumor and was withdrawn from the masked study. Additional dogs receiving APOQUEL were hospitalized for diagnosis and treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (one dog), transient bloody <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and stool (one dog), and <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> with <span class="product-label-link" type="condition" conceptid="79873" conceptname="Urolith">urolithiasis</span> (one dog).</p>
<p>In the 283 dogs that received APOQUEL, the following additional clinical signs were reported after beginning APOQUEL (percentage of dogs with at least one report of the clinical sign as a non-pre-existing finding): <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span> (12.0%), non-specified dermal lumps (12.0%), <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span> (9.9%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (9.2%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6.0%), histiocytoma (3.9%), <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> (3.5%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (3.2%), <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (2.8%), yeast <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> (2.5%), pododermatitis (2.5%), <span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipoma</span> (2.1%), <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> (1.4%), <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> (1.1%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.1%), <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> (1.1%), <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> (1.1%), and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> (0.7).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First"><span class="Underline">Control of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> Associated with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Allergic Dermatitis</span></span></p>
<p>In a masked field study to assess the effectiveness and safety of oclacitinib for the control of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> associated with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span> in dogs, 216 dogs treated with APOQUEL and 220 dogs treated with placebo (vehicle control) were evaluated for safety. During the 30-day study, there were no fatalities and no adverse reactions requiring hospital care. Adverse reactions reported (and percent of dogs affected) during Days 0-7 included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.3% APOQUEL, 0.9% placebo), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.3% APOQUEL, 1.8% placebo), <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (1.8% APOQUEL, 1.4% placebo), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (1.4% APOQUEL, 0% placebo), and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> (1.4% APOQUEL, 0% placebo). In most of these cases, signs spontaneously resolved with continued dosing. Five APOQUEL group dogs were withdrawn from study because of: darkening areas of skin and fur (1 dog); <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1 dog); <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> (1 dog); an inflamed footpad and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1 dog); and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (1 dog). Dogs in the APOQUEL group had a slight decrease in mean white blood cell counts (neutrophil, eosinophil, and monocyte counts) that remained within the normal reference range. Mean lymphocyte count for dogs in the APOQUEL group increased at Day 7, but returned to pretreatment levels by study end without a break in APOQUEL administration. Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased in 25% of APOQUEL group dogs, but mean <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> remained within the reference range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<p class="First"><span class="Underline">Continuation Field Study</span></p>
<p>After completing APOQUEL field studies, 239 dogs enrolled in an unmasked (no placebo control), continuation therapy study receiving APOQUEL for an unrestricted period of time. Mean time on this study was 372 days (range 1 to 610 days). Of these 239 dogs, one dog developed demodicosis following 273 days of APOQUEL administration. One dog developed dermal pigmented viral plaques following 266 days of APOQUEL administration. One dog developed a moderately severe <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span> after 272 days of APOQUEL administration; this <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> resolved with antimicrobial treatment and temporary discontinuation of APOQUEL. One dog was euthanized after developing abdominal <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> and <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> of unknown etiology after 450 days of APOQUEL administration. Six dogs were euthanized because of suspected malignant neoplasms: including thoracic metastatic, abdominal metastatic, splenic, frontal sinus, and intracranial neoplasms, and transitional cell carcinoma after 17, 120, 175, 49, 141, and 286 days of APOQUEL administration, respectively. Two dogs each developed a Grade II mast cell tumor after 52 and 91 days of APOQUEL administration, respectively. One dog developed low grade B-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> after 392 days of APOQUEL administration. Two dogs each developed an apocrine gland adenocarcinoma (one dermal, one anal sac) after approximately 210 and 320 days of APOQUEL administration, respectively. One dog developed a low grade oral spindle cell <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> after 320 days of APOQUEL administration.</p>
<p>To report suspected adverse events, for technical assistance or to obtain a copy of the MSDS, contact Zoetis Inc. at 1-888-963-8471 or www.zoetis.com.</p>
<p>For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">Clinical Pharmacology</span>:</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-10.1"></a><p></p>
<p class="First"><span class="Underline">Mechanism of Action</span></p>
<p>Oclacitinib inhibits the function of a variety of pruritogenic cytokines and pro-inflammatory cytokines, as well as cytokines involved in <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> that are dependent on JAK1 or JAK3 enzyme activity. It has little effect on cytokines involved in hematopoiesis that are dependent on JAK2. Oclacitinib is not a corticosteroid or an antihistamine.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-10.2"></a><p></p>
<p class="First"><span class="Underline">Pharmacokinetics</span></p>
<p>In dogs, oclacitinib maleate is rapidly and well absorbed following oral administration, with mean time to peak plasma concentrations (T<span class="Sub">max</span>) of less than 1 hour. Following oral administration of 0.4-0.6 mg oclacitinib/kg to 24 dogs, the mean (90% confidence limits [CL]) maximum concentration (C<span class="Sub">max</span>) was 324 (281, 372) ng/mL and the mean area under the plasma concentration-time curve from 0 and extrapolated to infinity (AUC<span class="Sub">0-inf</span>) was 1890 (1690, 2110) ng∙hr/mL. The prandial state of dogs does not significantly affect the rate or extent of absorption. The absolute bioavailability of oclacitinib maleate was 89%.</p>
<p>Oclacitinib has low protein binding with 66.3-69.7% bound in fortified canine plasma at nominal concentrations ranging from 10-1000 ng/mL. The apparent mean (95% CL) volume of distribution at steady-state was 942 (870, 1014) mL/kg body weight.</p>
<p>Oclacitinib is metabolized in the dog to multiple metabolites and one major oxidative metabolite was identified in plasma and urine. Overall the major clearance route is metabolism with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450 enzymes by oclacitinib is minimal; the inhibitory concentrations (IC<span class="Sub">50s</span>) are 50 fold greater than the observed C<span class="Sub">max</span> values at the use dose.</p>
<p>Mean (95% CL) total body oclacitinib clearance from plasma was low – 316 (237, 396) mL/h/kg body weight (5.3 mL/min/kg body weight). Following IV and PO administration, the terminal t<span class="Sub">1/2</span> appeared similar with mean values of 3.5 (2.2, 4.7) and 4.1 (3.1, 5.2) hours, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Effectiveness</span>:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Underline">Control of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></span></p>
<p>A double-masked, 112-day, controlled study was conducted at 18 U.S. veterinary hospitals. The study enrolled 299 client-owned dogs with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>. Dogs were randomized to treatment with APOQUEL (152 dogs: tablets administered at a dose of 0.4-0.6 mg/kg per dose twice daily for 14 days and then once daily) or placebo (147 dogs: vehicle control, tablets administered on the same schedule). During the study, dogs could not be treated with other drugs that could affect the assessment of effectiveness, such as corticosteroids, anti-histamines, or cyclosporine. Treatment success for <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> for each dog was defined as at least a 2 cm decrease from baseline on a 10 cm visual analog scale (VAS) in <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, assessed by the Owner, on Day 28. Treatment success for <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span> was defined as a 50% decrease from the baseline Canine <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span> Extent and Severity Index (CADESI) score, assessed by the Veterinarian, on Day 28. The estimated proportion of dogs with Treatment Success in Owner-assessed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> VAS score and in Veterinarian-assessed CADESI score was greater and significantly different for the APOQUEL group compared to the placebo group.</p>
<table width="60%">
<caption><span>Estimated Proportion of Dogs with Treatment Success, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span></span></caption>
<col align="center" valign="middle" width="34%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="22%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Effectiveness Parameter</th>
<th class="Rrule" align="center">APOQUEL</th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">P-value</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Owner-Assessed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> VAS</td>
<td class="Rrule" align="center">0.66 <br>(n = 131)</td>
<td class="Rrule" align="center">0.04 <br>(n = 133)</td>
<td class="Rrule" align="center">
<span class="Italics">p</span>&lt;0.0001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Veterinarian-Assessed CADESI</td>
<td class="Rrule" align="center">0.49 <br>(n = 134)</td>
<td class="Rrule" align="center">0.04 <br>(n = 134)</td>
<td class="Rrule" align="center">
<span class="Italics">p</span>&lt;0.0001</td>
</tr>
</tbody>
</table>
<p>Compared to the placebo group, mean Owner-assessed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> VAS scores (on Days 1, 2, 7, 14, and 28) and Veterinarian-assessed CADESI scores (on Days 14 and 28) were lower (improved) in dogs in the APOQUEL group. By Day 30, 86% (127/147) of the placebo group dogs and 15% (23/152) of the APOQUEL group dogs withdrew from the masked study because of worsening clinical signs, and had the option to enroll in an unmasked study and receive APOQUEL. For dogs that continued APOQUEL treatment beyond one month, the mean Owner-assessed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> VAS scores and Veterinarian-assessed CADESI scores continued to improve through study end at Day 112.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<p class="First"><span class="Underline">Control of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> Associated with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Allergic Dermatitis</span></span></p>
<p>A double-masked, 30-day, controlled study was conducted at 26 U.S. veterinary hospitals. The study enrolled 436 client-owned dogs with a history of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span> attributed to one or more of the following conditions: <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, flea <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, food <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, contact <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, and other/unspecified <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>. Dogs were randomized to treatment with APOQUEL (216 dogs: tablets administered at a dose of 0.4-0.6 mg/kg twice daily) or placebo (220 dogs: vehicle control, tablets administered twice daily). During the study, dogs could not be treated with other drugs that could affect the assessment of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> or dermal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as corticosteroids, anti-histamines, or cyclosporine. Treatment success for each dog was defined as at least a 2 cm decrease from baseline on a 10 cm visual analog scale (VAS) in <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, assessed by the Owner, on at least 5 of the 7 evaluation days. The estimated proportion of dogs with Treatment Success was greater and significantly different for the APOQUEL group compared to the placebo group.</p>
<table width="60%">
<caption><span>Owner-Assessed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> VAS Treatment Success, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Allergic Dermatitis</span></span></caption>
<col align="center" valign="middle" width="34%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="22%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Effectiveness Parameter</th>
<th class="Rrule" align="center">APOQUEL<br>(n = 203)</th>
<th class="Rrule" align="center">Placebo<br>(n = 204)</th>
<th class="Rrule" align="center">P-value</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="center">Estimated Proportion of Dogs with Treatment Success</td>
<td class="Rrule" align="center">0.67</td>
<td class="Rrule" align="center">0.29</td>
<td class="Rrule" align="center">
<span class="Italics">p</span>&lt;0.0001</td>
</tr></tbody>
</table>
<p>After one week of treatment, 86.4% of APOQUEL group dogs compared with 42.5% of placebo group dogs had achieved a 2 cm reduction on the 10 cm Owner-assessed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> VAS. On each of the 7 days, mean Owner-assessed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> VAS scores were lower in dogs in the APOQUEL group (See <a href="#fig1">Figure 1</a>). Veterinarians used a 10 cm VAS scale to assess each dog's <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>. After one week of treatment, the mean Veterinarian-assessed VAS <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> score for the dogs in the APOQUEL group was lower at 2.2 cm (improved from a baseline value of 6.2 cm) compared with the placebo group mean score of 4.9 cm (from a baseline value of 6.2 cm). For dogs that continued APOQUEL treatment beyond one week, the Veterinarian-assessed <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> scores continued to improve through study end at Day 30.</p>
<p><span class="Bold">Figure 1: Owner Assessed <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> VAS Scores by treatment for Days 0-7</span></p>
<p><a name="fig1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=275a2c51-9679-4f42-b8cc-21b04369a056&amp;name=apoquel-02.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AS"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Animal Safety</span>:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<p class="First"><span class="Underline">Margin of Safety in 12 Month Old Dogs</span></p>
<p>Oclacitinib maleate was administered to healthy, one-year-old Beagle dogs twice daily for 6 weeks, followed by once daily for 20 weeks, at 0.6 mg/kg (1X maximum exposure dose, 8 dogs), 1.8 mg/kg (3X, 8 dogs), and 3.0 mg/kg (5X, 8 dogs) oclacitinib for 26 weeks. Eight dogs received placebo (empty gelatin capsule) at the same dosage schedule. Clinical observations that were considered likely to be related to oclacitinib maleate included <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> and a dose-dependent increase in the number and frequency of interdigital <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span> (<span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>) on one or more feet during the study. Additional clinical observations were primarily related to the interdigital <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span> and included <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> (local <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasions</span>, <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabbing</span>/crusts, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of feet) and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> of peripheral nodes. Microscopic findings considered to be oclacitinib maleate-related included decreased cellularity (lymphoid) in Gut-Associated Lymphoid Tissue (GALT), spleen, thymus, cervical and mesenteric lymph node; and decreased cellularity of sternal and femoral bone marrow. Lymphoid <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and chronic active <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> was seen in lymph nodes draining feet affected with interdigital <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>. Five oclacitinib maleate-treated dogs had microscopic evidence of mild <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonia</span>.</p>
<p>Clinical pathology findings considered to be oclacitinib maleate-related included mild, dose-dependent reduction in hemoglobin, hematocrit, and reticulocyte counts during the twice daily dosing period with decreases in the leukocyte subsets of <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, eosinophils, and <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span>. Total proteins were decreased over time primarily due to the albumin fraction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<p class="First"><span class="Underline">Vaccine Response Study</span></p>
<p>An adequate immune response (serology) to killed <span class="product-label-link" type="condition" conceptid="377793" conceptname="Rabies">rabies</span> (RV), modified live canine distemper virus (CDV), and modified live canine parvovirus (CPV) vaccination was achieved in eight 16-week old vaccine naïve puppies that were administered oclacitinib maleate at 1.8 mg/kg oclacitinib (3X maximum exposure dose) twice daily for 84 days. For modified live canine parainfluenza virus (CPI), &lt; 80% (6 of 8) of the dogs achieved adequate serologic response. Clinical observations that were considered likely to be related to oclacitinib maleate treatment included enlarged lymph nodes, interdigital <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>, and pododermatitis. One oclacitinib maleate-treated dog (26-weeks-old) was euthanized on Day 74 after physical examination revealed the dog to be febrile, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargic</span>, with <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> mucous membranes and frank <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">blood in stool</span>. Necropsy revealed <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> of short duration and evidence of chronic <span class="product-label-link" type="condition" conceptid="316084" conceptname="Lymphadenitis">lymphadenitis</span> of mesenteric lymph nodes. During the three month recovery phase to this study, one oclacitinib maleate-treated dog (32-weeks old) was euthanized on Day 28 due to clinical signs which included enlarged prescapular lymph nodes, bilateral <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">epiphora</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, mild <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The dog showed an elevated white blood cell (WBC) count. Necropsy revealed lesions consistent with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> secondary to <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. Bone marrow <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was consistent with response to <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3"></a><p></p>
<p class="First"><span class="Underline">Margin of Safety in 6 Month Old Dogs</span></p>
<p>A margin of safety study in 6-month-old dogs was discontinued after four months due to the development of bacterial <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and generalized demodex mange <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in dogs in the high dose (3X and 5X) treatment groups, dosed at 1.8 and 3.0 mg/kg oclacitinib twice daily, for the entire study.</p>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Storage Conditions</span>:</p>
<p>APOQUEL should be stored at controlled room temperature between 20° to 25°C (68° to 77°F) with excursions between 15° to 40°C (59° to 104°F).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">How Supplied</span>:</p>
<p>APOQUEL tablets contain 3.6 mg, 5.4 mg, or 16 mg of oclacitinib as oclacitinib maleate per tablet. Each strength tablets are packaged in 20 and 100 count bottles. Each tablet is scored and marked with AQ and either an S, M, or L that correspond to the different tablet strengths on both sides.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">NADA #141-345, Approved by FDA</p>
<p>Made in Italy</p>
<p>Distributed by:<br>Zoetis Inc.<br>Kalamazoo, MI 49007</p>
<p>February 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 3.6 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">apoquel</span><span class="Sub">®</span><br>(oclacitinib tablet)</p>
<p>20 tablets</p>
<p><span class="Bold">3.6 mg</span></p>
<p>For Oral Use in Dogs Only<br><span class="Bold">Caution:</span> Federal (USA) law restricts this drug to use<br>by or on the order of a licensed veterinarian.<br><span class="Bold">Net Contents: </span>20 Tablets<br>NADA 141-345, Approved by FDA</p>
<p>Made in Italy<br>Distributed by:<br>Zoetis Inc., Kalamazoo, MI 49007</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="Principal Display Panel - 3.6 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=275a2c51-9679-4f42-b8cc-21b04369a056&amp;name=apoquel-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL  - 5.4 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">apoquel</span><span class="Sub">®</span><br>(oclacitinib tablet)</p>
<p>20 tablets</p>
<p><span class="Bold">5.4 mg</span></p>
<p>For Oral Use in Dogs Only<br><span class="Bold">Caution:</span> Federal (USA) law restricts this drug to use<br>by or on the order of a licensed veterinarian.<br><span class="Bold">Net Contents: </span>20 Tablets<br>NADA 141-345, Approved by FDA</p>
<p>Made in Italy<br>Distributed by:<br>Zoetis Inc., Kalamazoo, MI 49007</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="Principal Display Panel - 5.4 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=275a2c51-9679-4f42-b8cc-21b04369a056&amp;name=apoquel-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 16 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">apoquel</span><span class="Sub">®</span><br>(oclacitinib tablet)</p>
<p>20 tablets</p>
<p><span class="Bold">16 mg</span></p>
<p>For Oral Use in Dogs Only<br><span class="Bold">Caution:</span> Federal (USA) law restricts this drug to use<br>by or on the order of a licensed veterinarian.<br><span class="Bold">Net Contents: </span>20 Tablets<br>NADA 141-345, Approved by FDA</p>
<p>Made in Italy<br>Distributed by:<br>Zoetis Inc., Kalamazoo, MI 49007</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="Principal Display Panel - 16 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=275a2c51-9679-4f42-b8cc-21b04369a056&amp;name=apoquel-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>APOQUEL 		
					</strong><br><span class="contentTableReg">oclacitinib maleate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-8721</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>oclacitinib maleate</strong> (oclacitinib) </td>
<td class="formItem">oclacitinib maleate</td>
<td class="formItem">3.6 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">S</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-8721-1</td>
<td class="formItem">12  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54771-8721-2</td>
<td class="formItem">12  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141345</td>
<td class="formItem">01/20/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>APOQUEL 		
					</strong><br><span class="contentTableReg">oclacitinib maleate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-8722</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>oclacitinib maleate</strong> (oclacitinib) </td>
<td class="formItem">oclacitinib maleate</td>
<td class="formItem">5.4 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-8722-1</td>
<td class="formItem">12  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54771-8722-2</td>
<td class="formItem">12  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141345</td>
<td class="formItem">01/20/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>APOQUEL 		
					</strong><br><span class="contentTableReg">oclacitinib maleate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-8723</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>oclacitinib maleate</strong> (oclacitinib) </td>
<td class="formItem">oclacitinib maleate</td>
<td class="formItem">16 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">L</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-8723-1</td>
<td class="formItem">12  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54771-8723-2</td>
<td class="formItem">12  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141345</td>
<td class="formItem">01/20/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Zoetis Inc.
							(828851555)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Italia S.r.l.</td>
<td class="formItem"></td>
<td class="formItem">431227388</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">API MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ce92d14f-6d3b-4334-ab6d-9da3d11aa92c</div>
<div>Set id: 275a2c51-9679-4f42-b8cc-21b04369a056</div>
<div>Version: 2</div>
<div>Effective Time: 20140306</div>
</div>
</div> <div class="DistributorName">Zoetis Inc.</div></p>
</body></html>
